Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Recruiting now

Conditions studied: Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC

In brief

Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).

Key facts

Study ID

NCT06327178

Run by

Nanfang Hospital, Southern Medical University

People needed

20

Starts

2023-10-01

Expected to finish

2025-06-30

Last updated by the study team

2025-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age≥18 years at the time of signing informed consent;
• Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8);
• Previously received SBRT and concurrent PD-1 blockade treatment；
• Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria.

You may not qualify if…

• Patients who cannot be adequately followed up;
• Has a known additional malignancy that is progressing or requires active treatment.

Where it is running

• Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.